Eternox is a biotech company founded by Dr. Hankil Jeong, an intensivist and physician-scientist at Seoul National University Bundang Hospital. The company is developing ROSorber, a first-in-class therapeutic device that removes reactive oxygen species (ROS) from the bloodstream to fundamentally treat septic shock.
ROSorber has demonstrated 100% survival in preclinical studies using refractory septic shock animal models, and Eternox aims to obtain FDA Breakthrough Device Designation (BDD) and advance into global clinical trials. Given the significant unmet need and the lack of survival improvement with current standard-of-care treatments, Eternox’s technology has the potential to establish a new treatment paradigm in the large and underserved sepsis market.
